Central African RepublicTuberculosis profile
Population  2015 4.9 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 2.2 (1.3–3.4) 45 (26–70)
Mortality (HIV+TB only) 2.7 (1–5.3) 55 (20–107)
Incidence  (includes HIV+TB) 19 (12–27) 391 (253–558)
Incidence (HIV+TB only) 8.6 (5.3–13) 176 (107–262)
Incidence (MDR/RR-TB)** 0.21 (0–0.45) 4.3 (0–9.2)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 1.3 (0.63–1.9) 7.2 (3.6–11) 8.4 (4.2–13)
Males 1 (0.59–1.4) 9.7 (6.6–13) 11 (7.2–14)
Total 2.3 (1.4–3.1) 17 (13–21) 19 (12–27)
TB case notifications, 2015  
Total cases notified 10 799
Total new and relapse 10 459
          - % tested with rapid diagnostics at time of diagnosis 1%
          - % with known HIV status 48%
          - % pulmonary 82%
          - % bacteriologically confirmed among pulmonary 61%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 55% (38–84)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.27 (0.13–0.48)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive 1 963 39%
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  140
(23–250)
Estimated % of TB cases with MDR/RR-TB 0.4% (0–1.6) 14% (6.9–21)  
% notified tested for rifampicin resistance <1% 14% 105
MDR/RR-TB cases tested for resistance to second-line drugs   38
Laboratory-confirmed cases MDR/RR-TB: 62, XDR-TB: 2
Patients started on treatment **** MDR/RR-TB: 38, XDR-TB: 0
Treatment success rate and cohort size Success Cohort
New cases registered in 2014 70% 9 209
Previously treated cases registered in 2014 64% 476
HIV-positive TB cases, all types, registered in 2014 68% 2 056
MDR/RR-TB cases started on second-line treatment in 2013 81% 16
XDR-TB cases started on second-line treatment in 2013   0
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions) 1.8
Funding source: 15% domestic, 55% international, 31% unfunded
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New cases
   Previously treated cases
   HIV-positive   MDR/RR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Unfunded
__Funded internationally
__Funded domestically
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-08 Data: www.who.int/tb/data